Misplaced Pages

Navafenterol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
Navafenterol
Identifiers
IUPAC name
  • amino]methyl]benzotriazol-1-yl]propyl-methylamino]cyclohexyl] 2-hydroxy-2,2-dithiophen-2-ylacetate
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC38H42N6O6S2
Molar mass742.91 g·mol
3D model (JSmol)
SMILES
  • CN(CCCN1C2=C(C=C(C=C2)CNC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)N=N1)C5CCC(CC5)OC(=O)C(C6=CC=CS6)(C7=CC=CS7)O
InChI
  • InChI=InChI=1S/C38H42N6O6S2/c1-43(25-8-10-26(11-9-25)50-37(48)38(49,33-5-2-19-51-33)34-6-3-20-52-34)17-4-18-44-30-14-7-24(21-29(30)41-42-44)22-39-23-32(46)27-12-15-31(45)36-28(27)13-16-35(47)40-36/h2-3,5-7,12-16,19-21,25-26,32,39,45-46,49H,4,8-11,17-18,22-23H2,1H3,(H,40,47)/t25?,26?,32-/m0/s1
  • Key:ZNKWRAKPQQZLNX-FFJARJNZSA-N

Navafenterol is an investigational drug that had been evaluated for chronic obstructive pulmonary disease. It is a Beta2 agonist and a muscarinic antagonist. Further development has been discontinued for strategic reasons.

References

  1. Antoniu SA, Handra CM, Rascu A, Barbu BA, Chirap Mitulschi I (April 2023). "Navafenterol for chronic obstructive pulmonary disease therapy". Expert Opinion on Investigational Drugs. 32 (4): 283–290. doi:10.1080/13543784.2023.2199920. PMID 37017626. S2CID 257953939.
  2. "Navafenterol - AstraZeneca". AdisInsight. Springer Nature Switzerland AG.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: